{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:30:37Z","timestamp":1773685837949,"version":"3.50.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9i) have recently emerged as promising therapeutic agents for lowering low-density lipoprotein cholesterol and reducing the risk of cardiovascular events. Moreover, preliminary evidence from randomized controlled trials (RCTs) suggests that PCSK9i may also offer beneficial effects for patients following venous thromboembolism (VTE), with the most significant reductions in risk appearing over time, particularly beyond the first year of treatment. However, there is a lack of randomized controlled data supporting their efficacy and safety in conjunction with standard anticoagulation therapy. This article aims to critically evaluate the existing evidence for the use of PCSK9i as a complementary therapy for VTE risk reduction, while also identifying unmet clinical and research needs and proposing potential strategies to address these knowledge gaps.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvae076","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:23:21Z","timestamp":1729038201000},"page":"719-724","source":"Crossref","is-referenced-by-count":5,"title":["Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-1292","authenticated-orcid":false,"given":"Marco","family":"Zuin","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara , Via Luigi Borsari 46, Ferrara 44121 ,","place":["Italy"]},{"name":"Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova , via Giustiniani 2, Padova 35128 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-9482","authenticated-orcid":false,"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan , Milan 20133 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Dalla Valle","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West Vicenza General Hospital , Arzignano 36071 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catia","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale Mauriziano Umberto I , Torino 10128 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation Unit, Cardiology 4, ASST Grande Ospedale Metropolitano Niguarda , Milano 20162 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mojoli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Santa Maria degli Angeli, Azienda Ospedaliera Friuli Occidentale (ASFO) , Pordenone 33170 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Policlinico Umberto I , Roma 00161 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ciccirillo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale Vito Fazzi , Lecce 73100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Madrid","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN Cardarelli , Napoli 80131 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Sant'Anna e San Sebastiano Hospital , Caserta 81100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-8884","authenticated-orcid":false,"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale Generale Regionale \u201cF. Miulli\u201d , Acquaviva delle Fonti 70021 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital , Roma 00135 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[{"name":"Cardiology Unit, ASST Grande Ospedale Metropolitano Niguarda , Milano 36071 ,","place":["Italy"]},{"name":"President, Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) , Florence 50121 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Temporelli","sequence":"additional","affiliation":[{"name":"Division of Cardiac Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS , Gattico-Veruno 28013 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Working Group on Cardiological Chronicity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"2025011107294959800_bib1","doi-asserted-by":"crossref","first-page":"e016784","DOI":"10.1161\/JAHA.120.016784","article-title":"Time trends in pulmonary embolism mortality rates in the United States, 1999 to 2018","volume":"9","author":"Martin","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025011107294959800_bib2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis","volume":"348","author":"Prandoni","year":"2003","journal-title":"N Engl J Med"},{"key":"2025011107294959800_bib3","doi-asserted-by":"crossref","first-page":"e4495","DOI":"10.1097\/MD.0000000000004495","article-title":"Venous thromboembolism has the same risk factors as atherosclerosis: a PRISMA-compliant systemic review and meta-analysis","volume":"95","author":"Mi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025011107294959800_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1160\/TH08-06-0360","article-title":"Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se","volume":"100","author":"Ageno","year":"2008","journal-title":"Thromb Haemost"},{"key":"2025011107294959800_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0038-1625985","article-title":"Anticoagulant preferences and concerns among venous thromboembolism patients","volume":"118","author":"Lutsey","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025011107294959800_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12185-023-03651-6","article-title":"Current challenges in the prevention and management of post-thrombotic syndrome-towards improved prevention","volume":"118","author":"Wang","year":"2023","journal-title":"Int J Hematol"},{"key":"2025011107294959800_bib7","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.rpth.2024.102424","article-title":"Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use","volume":"8","author":"Khairani","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"2025011107294959800_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2025011107294959800_bib9","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"key":"2025011107294959800_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3949\/ccjm.77a.09077","article-title":"Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed","volume":"77","author":"Perez","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"2025011107294959800_bib11","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1185\/03007990903052591","article-title":"Statins and venous thromboembolism: a novel effect of statins?","volume":"25","author":"Paraskevas","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2025011107294959800_bib12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1742-1241.2010.02439.x","article-title":"Statin use and the prevention of venous thromboembolism: a meta-analysis","volume":"64","author":"Agarwal","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2025011107294959800_bib13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCRESAHA.117.311015","article-title":"PCSK9 inhibition to reduce cardiovascular risk: tempering expectations","volume":"120","author":"Waters","year":"2017","journal-title":"Circ Res"},{"key":"2025011107294959800_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.acvd.2015.11.007","article-title":"Statins and prevention of venous thromboembolism: myth or reality?","volume":"109","author":"Gaertner","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"2025011107294959800_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"2025011107294959800_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1160\/TH06-05-0231","article-title":"Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study","volume":"96","author":"Bova","year":"2006","journal-title":"Thromb Haemost"},{"key":"2025011107294959800_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2796.2007.01815.x","article-title":"Links between arterial and venous disease","volume":"262","author":"Prandoni","year":"2007","journal-title":"J Intern Med"},{"key":"2025011107294959800_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(98)00037-9","article-title":"The atherogenic lipoprotein phenotype and vascular endothelial dysfunction","volume":"138","author":"Sattar","year":"1998","journal-title":"Atherosclerosis"},{"key":"2025011107294959800_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00001721-199801000-00006","article-title":"Platelet activation supports the development of venous thrombosis in hyperlipidemic rats","volume":"9","author":"Cignarella","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2025011107294959800_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1055\/s-0038-1642518","article-title":"Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet","volume":"71","author":"Bladbjerg","year":"1994","journal-title":"Thromb Haemost"},{"key":"2025011107294959800_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.5551\/jat.3079","article-title":"Idiopathic venous thrombosis is associated with preclinical atherosclerosis","volume":"17","author":"Jezovnik","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"2025011107294959800_bib22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1538-7836.2006.02058.x","article-title":"Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis","volume":"4","author":"Prandoni","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2025011107294959800_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am J Pathol"},{"key":"2025011107294959800_bib24","doi-asserted-by":"crossref","first-page":"106439","DOI":"10.1016\/j.phrs.2022.106439","article-title":"Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9","volume":"184","author":"Ferri","year":"2022","journal-title":"Pharmacol Res"},{"key":"2025011107294959800_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol Rev"},{"key":"2025011107294959800_bib26","doi-asserted-by":"crossref","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025011107294959800_bib27","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"2025011107294959800_bib28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025011107294959800_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2025011107294959800_bib30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"2025011107294959800_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"Danik","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2025011107294959800_bib32","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025011107294959800_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"Mclean","year":"1987","journal-title":"Nature"},{"key":"2025011107294959800_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11789-019-00101-8","article-title":"Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?","volume":"14","author":"Nave","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"2025011107294959800_bib35","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/eurheartj\/ehae361","article-title":"Lipid lowering for prevention of venous thromboembolism: a network meta-analysis","author":"Farmakis","year":"2024","journal-title":"Eur Heart J"},{"key":"2025011107294959800_bib36","doi-asserted-by":"crossref","first-page":"14360","DOI":"10.1038\/s41598-017-14307-x","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) deficiency is protective against venous thrombosis in mice","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"2025011107294959800_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.thromres.2011.06.027","article-title":"Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis","volume":"129","author":"Emmerechts","year":"2012","journal-title":"Thromb Res"},{"key":"2025011107294959800_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1160\/TH12-05-0316","article-title":"In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process","volume":"109","author":"Golder","year":"2013","journal-title":"Thromb Haemost"},{"key":"2025011107294959800_bib39","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCRESAHA.108.172064","article-title":"A specific CD36- dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein","volume":"102","author":"Chen","year":"2008","journal-title":"Circ Res"},{"key":"2025011107294959800_bib40","first-page":"30171","article-title":"Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases","author":"Hofmann","year":"2017"},{"key":"2025011107294959800_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/ATVBAHA.120.315421","article-title":"Role of LOX-1 (lectin-like oxidized low-density lipoprotein receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use","volume":"41","author":"Barreto","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025011107294959800_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2014.08.041","article-title":"LDL oxidation by platelets propagates platelet activation via an oxidative stressmediated mechanism","volume":"237","author":"Carnevale","year":"2014","journal-title":"Atherosclerosis"},{"key":"2025011107294959800_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1172\/JCI107971","article-title":"Platelet hypersensitivity induced by cholesterol incorporation","volume":"55","author":"Shattil","year":"1975","journal-title":"J Clin Invest"},{"key":"2025011107294959800_bib44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"2025011107294959800_bib45","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"key":"2025011107294959800_bib46","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Seidah NG proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"2025011107294959800_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.thromres.2022.03.021","article-title":"Pleiotropic effects of PCSK9-inhibition on hemostasis: anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression","volume":"213","author":"Paciullo","year":"2022","journal-title":"Thromb Res"},{"key":"2025011107294959800_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/2047487319831500","article-title":"Changes in circulating pro-protein convertase subtilisin\/kexin type 9 levels\u2014experimental and clinical approaches with lipid-lowering agents","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2025011107294959800_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/antiox9040296","article-title":"PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation","volume":"9","author":"Cammisotto","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"2025011107294959800_bib50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025011107294959800_bib51","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1161\/CIRCRESAHA.121.318225","article-title":"Inflammation, infection and Venous Thromboembolism","volume":"128","author":"Colling","year":"2021","journal-title":"Circ Res"},{"key":"2025011107294959800_bib52","doi-asserted-by":"crossref","first-page":"13176","DOI":"10.3390\/ijms232113176","article-title":"Immunothrombosis and the role of platelets in Venous Thromboembolic diseases","volume":"23","author":"Heestermans","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025011107294959800_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0035-1570079","article-title":"The role of platelets in Venous Thromboembolism","volume":"42","author":"Montoro-Garc\u00eda","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"2025011107294959800_bib54","first-page":"785","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova","year":"2017","journal-title":"Eur Heart J"},{"key":"2025011107294959800_bib55","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/ATVBAHA.118.310731","article-title":"Platelets drive thrombus propagation in a hematocrit and glycoprotein VI-dependent manner in an in vitro Venous Thrombosis model","volume":"38","author":"Lehmann","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025011107294959800_bib56","doi-asserted-by":"crossref","first-page":"684920","DOI":"10.3389\/fcvm.2021.684920","article-title":"Soluble platelet release factors as biomarkers for cardiovascular disease","volume":"8","author":"Baidildinova","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025011107294959800_bib57","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jtha.2023.04.038","article-title":"Plasma levels of P-selectin and future risk of incident venous thromboembolism","volume":"21","author":"Swamy","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2025011107294959800_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.blre.2014.03.003","article-title":"Aspirin for prevention and treatment of venous thromboembolism","volume":"28","author":"Becattini","year":"2014","journal-title":"Blood Rev"},{"key":"2025011107294959800_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2022.11.023","article-title":"Translational insights into mechanisms underlying residual venous obstruction and the role of factor XI, P-selectin and GPVI in recurrent venous thromboembolism","volume":"221","author":"Iding","year":"2023","journal-title":"Thromb Res"},{"key":"2025011107294959800_bib60","doi-asserted-by":"crossref","first-page":"1039843","DOI":"10.3389\/fimmu.2022.1039843","article-title":"Platelet in thrombo-inflammation: unraveling new therapeutic targets","volume":"13","author":"Sharma","year":"2022","journal-title":"Front Immunol"},{"key":"2025011107294959800_bib61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.amepre.2022.10.010","article-title":"Trends in lipid-lowering prescriptions: increasing use of guideline-concordant pharmacotherapies, U.S., 2017\u20122022","volume":"64","author":"Sekkarie","year":"2023","journal-title":"Am J Prev Med"},{"key":"2025011107294959800_bib62","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14740338.2023.2203488","article-title":"There is no single gold standard study design (RCTs are not the gold standard)","volume":"22","author":"Gerstman","year":"2023","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae076\/60542072\/pvae076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/719\/60542072\/pvae076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/719\/60542072\/pvae076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T07:30:15Z","timestamp":1736580615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/8\/719\/7823293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae076","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,15]]}}}